Seroepidemiology study suggests EV-A71 vaccine effective in Guangzhou, China

Notes Reviewers’ Notes

Enterovirus A71 (EV-A71) is a significant hand-foot-mouth disease (HFMD) etiology. The inactivated EV-A71 vaccines were approved in China in 2016. However, the seroprevalence of EV-A71 after the vaccine application and its potential association with the EV-A71 epidemic in the population are rarely studied.

The authors of this article analyzed the incidence of EV-A71 infection and seroepidemiology in Guangzhou City, China. From 2019 to 2021, 167,920 clinically confirmed HFMD cases were reported in Guangzhou. In 6,868 enterovirus-positive samples, Coxsackievirus A6 and Coxsackievirus A16 were dominant genotypes, and only 3 EV-A71-positive samples were detected, highlighting the deficient epidemic activity of EV-A71. Microneutralization assay was performed on 1,000 representative serum samples. Notably, the seroprevalence and geometric mean titer (GMT) decreased significantly in 2020, and that in the < 3-year age group were increased and even higher than that in 3-5-year age group in 2019 and 2021, which was contrary to the authors previous surveillance result and other studies in Guangzhou. Furthermore, a moderate decline of GMT level was observed following the vaccination, but the seropositive serums were still detected for 49 months after second immunization, suggesting the long-term persistence of the immunity.

This seroepidemiology study revealed relatively higher neutralizing antibody activity in the susceptible population after the EV-A71 vaccine was adopted in 2016 in Guangzhou. It may be one of the reasons for the lower epidemic activity of EV-A71 in Guangzhou from 2019 to 2021.


  • EV-A71 as a major agent of HFMD was rarely detected after 2019 in Guangzhou, China.
  • The increased seroprevalence and nAb titer was observed after vaccine adoption.
  • The enhanced immunity in susceptible populations may lower viral epidemic activity.

Compuscript Ltd

Journal reference:

Lian, H., et al. (2023). Seroprevalence of human enterovirus A71 in Guangzhou, China, 2019–2021. Biosafety and Health.

Posted in: Medical Research News | Disease/Infection News

Tags: Antibody, Assay, Enterovirus, Foot, immunity, Immunization, Vaccine

Comments (0)
Source: Read Full Article